Leerink Swann Downgrades Pharmasset (VRUS) to Market Perform; A Befitting End to a Remarkable Biotech Story
Tweet Send to a FriendGet Alerts VRUS Hot Sheet
Price: $136.97 --0%
Rating Summary:
5 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 41 | New: 13
Rating Summary:
5 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 41 | New: 13
Trade VRUS Now!
Leerink Swann downgraded Pharmasset (NASDAQ: VRUS) from Outperform to Market Perform, price target raised from $100 to $137.
Leerink analyst says, "Bottom Line: We believe the acquisition of Pharmasset by Gilead (Nasdaq: GILD) announced yesterday validates our bullish outlook for the transformation in hepatitis C treatment and prospects of interferon-free regimens. The acquisition price of ~$11B likely sets a record for valuation of a development-stage company that could be more than 10x the previous largest similar acquisition that we can think of (acquisition of Cougar Biotechnology by Johnson and Johnson (NYSE: JNJ)). As a result of the announcement of the acquisition -- unanimously approved by VRUS's board of directors -- we are downgrading VRUS shares."
For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.
Shares of Pharmasset closed at $134.14 yesterday, with a 52 week range of $41.26-$137.81.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Leerink analyst says, "Bottom Line: We believe the acquisition of Pharmasset by Gilead (Nasdaq: GILD) announced yesterday validates our bullish outlook for the transformation in hepatitis C treatment and prospects of interferon-free regimens. The acquisition price of ~$11B likely sets a record for valuation of a development-stage company that could be more than 10x the previous largest similar acquisition that we can think of (acquisition of Cougar Biotechnology by Johnson and Johnson (NYSE: JNJ)). As a result of the announcement of the acquisition -- unanimously approved by VRUS's board of directors -- we are downgrading VRUS shares."
For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.
Shares of Pharmasset closed at $134.14 yesterday, with a 52 week range of $41.26-$137.81.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Barrington Research Downgrades Align Technology (ALGN) to Market Perform
- Keefe, Bruyette & Woods Downgrades Artisan Partners Asset Management (APAM) to Market Perform
Create E-mail Alert Related Categories
Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
